GLOBUS MEDICAL INC

Day range

$80.63 – $81.91

Open

$81.50

Prev close

$81.41

Volume

1.03M

Market cap

$10.93B

Shares out

134.26M

P/E

20.41

P/S

3.48

P/B

2.29

P/FCF

14.47

ROE

11.2%

ROA

9.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsJun 4, 2026

  At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below. Proposal 1 - Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders. Each of the director nominees listed below were elected by the Company's stockholders at the Annual Meeting to serve a three-year term on the Board.

• Director departureMar 23, 2026

  On March 23, 2026, John A. DeFord, Ph.D., a member of the Board of Directors (the "Board") of Globus Medical, Inc. (the "Company"), informed the Company of his resignation from the Board effective immediately. Dr. DeFord's decision was not a result of any disagreement with the Company.

• Guidance issuance or updateJan 7, 2026

  The press release also included preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026.

• Ceo departureJul 21, 2025

  On July 18, 2025, Daniel T. Scavilla notified the Chairman of the Board of Directors (the "Board") of the Company of his resignation from the Board and from his positions as President and Chief Executive Officer of the Company, in each case effective July 18, 2025. Mr. Scavilla's resignation was not due to any disagreement on any matter relating to the Company's operations, financials, policies, or practices.

• Annual meeting resultsJun 5, 2025

  The Annual Meeting was held on June 4, 2025. At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below. Proposal 1: The individuals listed below were each elected at the Annual Meeting to serve a three-year term on the Company's Board of Directors.

• WSTWest Pharmaceutical Services, Inc.+0.66%
• VCYTVeracyte, Inc.+0.56%

Days to cover

5.1

Short interest

8.44M

Avg volume

1.64M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
  positiveZacks Investment Research· Oct 23, 2026
• INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?
  positiveZacks Investment Research· Oct 23, 2026
• FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
  positiveZacks Investment Research· Oct 23, 2026
• DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
  neutralZacks Investment Research· Oct 22, 2026
• BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
  positiveZacks Investment Research· Oct 22, 2026